UCB Pharma Limited

208 Bath Road, Slough, Berkshire, SL1 3WE
Telephone: +44 (0)1753 534 655
Medical Information Direct Line: +44 (0)1753 447 690
Medical Information e-mail: Medicalinformationuk@ucb.com
Customer Care direct line: +44 (0) 1773 510123

Patient Information Leaflet last updated on the eMC: 17/12/2010
PIL Perdix 7.5 mg and 15 mg

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 17/12/2010 and displayed until Current
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change of contra-indications
Updated on 24/06/2010 and displayed until 17/12/2010
Reasons for adding or updating:
  • Change to name of manufacturer
Updated on 22/06/2010 and displayed until 24/06/2010
Reasons for adding or updating:
  • Change to date of revision
  • Change to drug interactions
Updated on 03/04/2009 and displayed until 22/06/2010
Reasons for adding or updating:
  • Change of licence holder
  • Change to Marketing Authorisation Holder
Updated on 25/02/2009 and displayed until 03/04/2009
Reasons for adding or updating:
  • Change of contra-indications
  • Change to information about pregnancy or lactation
  • Change due to user-testing of patient information
Updated on 24/10/2007 and displayed until 25/02/2009
Reasons for adding or updating:
  • Addition of joint PIL covering all presentations
Updated on 09/06/2006 and displayed until 24/10/2007
Reasons for adding or updating:
  • Improved Electronic Presentation
  • PIL Company name change or merger
Updated on 08/06/2006 and displayed until 09/06/2006
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Active Ingredients/Generics

 
   moexipril hydrochloride